A Day Up For Innate Pharma S.A.
Innate Pharma S.A. (IPHA:NASDAQ) soared at $2.17, representing a gain of 64.4%. On Thu, May 14, 2026, IPHA:NASDAQ touched a New 2-Week High of $2.17. The stock appeared on our News Catalysts scanner on Wed, May 13, 2026 at 03:04 AM in the 'EARNINGS' category. From Thu, Apr 30, 2026, the stock recorded 40.00% Up Days and 27.27% Green Days
About Innate Pharma S.A. (IPHA:NASDAQ)
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies.
Top 10 Gainers:
- Smart Powerr Corp. (CREG:NASDAQ), 257.15%
- Leslie's, Inc. (LESL:NASDAQ), 144.76%
- Eason Technology Limited (DXF:NYSEMKT), 130.2%
- Mainz Biomed N.V. (QUCY:NASDAQ), 123.88%
- J-Star Holding Co. Ltd. (YMAT:NASDAQ), 118.87%
- Robo.ai Inc Cl B Ord (AIIO:NASDAQ), 116.09%
- Snail, Inc. (SNAL:NASDAQ), 115.1%
- Mobix Labs, Inc. (MOBX:NASDAQ), 78.74%
- Concorde International Group Ltd (YOOV:NASDAQ), 77.79%
- Innate Pharma S.A. (IPHA:NASDAQ), 64.39%